| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at … CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ... Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002 | 1529 | 2002 |
| Targeting FLT3 mutations in AML: review of current knowledge and evidence N Daver, RF Schlenk, NH Russell, MJ Levis Leukemia 33 (2), 299-312, 2019 | 872 | 2019 |
| Assessment of minimal residual disease in standard-risk AML A Ivey, RK Hills, MA Simpson, JV Jovanovic, A Gilkes, A Grech, Y Patel, ... New England Journal of Medicine 374 (5), 422-433, 2016 | 867 | 2016 |
| Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial AK Burnett, RK Hills, D Milligan, L Kjeldsen, J Kell, NH Russell, JAL Yin, ... Journal of clinical oncology 29 (4), 369-377, 2011 | 739 | 2011 |
| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NM Dahir, ... Journal of clinical oncology 33 (33), 3911-3920, 2015 | 621 | 2015 |
| Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) N Schmitz, P Dreger, M Suttorp, EB Rohwedder, T Haferlach, H Löffler, ... Blood 85 (6), 1666-1672, 1995 | 615 | 1995 |
| Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet MA Sanz, P Fenaux, MS Tallman, EH Estey, B Löwenberg, T Naoe, ... Blood, The Journal of the American Society of Hematology 133 (15), 1630-1643, 2019 | 526 | 2019 |
| Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial AK Burnett, NH Russell, RK Hills, D Bowen, J Kell, S Knapper, YG Morgan, ... The lancet oncology 16 (13), 1295-1305, 2015 | 509 | 2015 |
| The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhaeuser, ... Nature reviews Clinical oncology 9 (10), 579-590, 2012 | 471 | 2012 |
| Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial AK Burnett, NH Russell, RK Hills, AE Hunter, L Kjeldsen, J Yin, ... Journal of clinical oncology 31 (27), 3360-3368, 2013 | 453 | 2013 |
| Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia AK Burnett, NH Russell, RK Hills, J Kell, S Freeman, L Kjeldsen, ... J Clin Oncol 30 (32), 3924-3931, 2012 | 453 | 2012 |
| The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis GJ Morgan, WM Gregory, FE Davies, SE Bell, AJ Szubert, JM Brown, ... Blood, The Journal of the American Society of Hematology 119 (1), 7-15, 2012 | 450 | 2012 |
| Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) OC Goodyear, M Dennis, NY Jilani, J Loke, S Siddique, G Ryan, ... Blood, The Journal of the American Society of Hematology 119 (14), 3361-3369, 2012 | 437 | 2012 |
| Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ... The Lancet Oncology 20 (7), 984-997, 2019 | 433 | 2019 |
| Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working … SP Robinson, AH Goldstone, S Mackinnon, A Carella, N Russell, ... Blood, The Journal of the American Society of Hematology 100 (13), 4310-4316, 2002 | 429 | 2002 |
| Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at … G Gahrton, H Svensson, M Cavo, J Apperley, A Bacigalupo, B Björkstrand, ... British journal of haematology 113 (1), 209-216, 2001 | 411 | 2001 |
| Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma … A Sureda, S Robinson, C Canals, AM Carella, MA Boogaerts, D Caballero, ... Journal of Clinical Oncology 26 (3), 455-462, 2008 | 399 | 2008 |
| Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize … AC Rawstron, B Kennedy, PAS Evans, FE Davies, SJ Richards, ... Blood, The Journal of the American Society of Hematology 98 (1), 29-35, 2001 | 354 | 2001 |
| Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow … P Ljungman, KN Ward, BNA Crooks, A Parker, R Martino, PJ Shaw, ... Bone marrow transplantation 28 (5), 479-484, 2001 | 341 | 2001 |
| Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia SD Freeman, P Virgo, S Couzens, D Grimwade, N Russell, RK Hills, ... Journal of Clinical Oncology 31 (32), 4123-4131, 2013 | 338 | 2013 |
Robert HillsUniversity of OxfordVerified email at ndph.ox.ac.uk
